Low-dose dasatinib seems to be safe and effective in intolerant patients with CML
Low-dose dasatinib seems to be safe and effective in intolerant patients with chronic phase (CP) chronic myelogenous leukaemia (CML), two case reports and review of the literature showed.
Low-dose dasatinib seems to be safe and effective in intolerant patients with CML
08 Sep 2026
